Halozyme Therapeutics (HALO) Tops Q2 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $131.18 --0%
EPS Growth %: +32.6%
Financial Fact:
Selling, general and administrative: 11.6M
Today's EPS Names:
TFS, PBNK, FNRN, More
EPS Growth %: +32.6%
Financial Fact:
Selling, general and administrative: 11.6M
Today's EPS Names:
TFS, PBNK, FNRN, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of $0.02, $0.11 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $43.4 million versus the consensus estimate of $25.12 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TFS Financial (TFSL) Reports In-Line Q4 EPS
- Pinnacle Bank (PBNK) Tops Q3 EPS by 4c
- Rhinebeck Bancorp (RBKB) Tops Q3 EPS by 21c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
